OPKO Health’s (OPK) “Outperform” Rating Reaffirmed at Barrington Research

Barrington Research restated their outperform rating on shares of OPKO Health (NASDAQ:OPK) in a report released on Thursday,Benzinga reports. The firm currently has a $2.25 target price on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. initiated coverage on shares of OPKO Health in a research note on Friday, April 25th. They issued a “neutral” rating on the stock. StockNews.com upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd. Finally, HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Monday, April 7th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, OPKO Health presently has an average rating of “Moderate Buy” and an average price target of $2.75.

OPKO Health Stock Performance

Shares of OPK opened at $1.39 on Thursday. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. OPKO Health has a 52-week low of $1.15 and a 52-week high of $2.04. The company has a 50-day simple moving average of $1.61 and a 200-day simple moving average of $1.57. The company has a market capitalization of $930.10 million, a PE ratio of -7.29 and a beta of 1.42.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The firm had revenue of $149.90 million during the quarter, compared to analysts’ expectations of $163.13 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business’s revenue for the quarter was down 13.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.12) earnings per share. Equities research analysts predict that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 200,000 shares of the stock in a transaction dated Monday, March 17th. The stock was acquired at an average price of $1.74 per share, with a total value of $348,000.00. Following the completion of the transaction, the chief executive officer now directly owns 213,501,448 shares in the company, valued at approximately $371,492,519.52. This trade represents a 0.09 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders have bought 767,434 shares of company stock worth $1,238,312. Corporate insiders own 49.69% of the company’s stock.

Institutional Trading of OPKO Health

Institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of OPKO Health by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock worth $275,000 after buying an additional 8,064 shares during the period. Two Sigma Advisers LP increased its stake in OPKO Health by 2.3% during the fourth quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock worth $560,000 after acquiring an additional 8,396 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in OPKO Health by 75.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 12,417 shares during the last quarter. Comerica Bank lifted its stake in shares of OPKO Health by 18.2% in the 4th quarter. Comerica Bank now owns 106,369 shares of the biotechnology company’s stock valued at $156,000 after purchasing an additional 16,369 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of OPKO Health by 4.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 455,521 shares of the biotechnology company’s stock worth $670,000 after purchasing an additional 18,571 shares during the period. 64.63% of the stock is owned by hedge funds and other institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.